Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Berard

Internal Medicine College Park, MD Medical Doctor

NPI 1366459877 CMS profile 152637

7305 Baltimore Ave, #107, College Park, MD 20740

Open in the dashboard

General payments

$4,907

73 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Berard of College Park, MD is reported in the CMS Open Payments database as having received $4,907 across 73 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $233 12
2024 General $498 25
2023 General $488 27
2022 General $3,187 4
2021 General $450 2
2020 General $16 1
2019 General $34 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Berard
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Michael Berard were reported at $233. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Michael Berard Internal Medicine median Middle half National median
2019 $34 $159 $48–$570 $163
2020 $16 $119 $33–$402 $114
2021 $450 $135 $37–$521 $132
2022 $3,187 $141 $42–$496 $149
2023 $488 $149 $45–$519 $160
2024 $498 $154 $47–$537 $164
2025 $233 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $3,572 6 payments
  2. Novo Nordisk Inc $736 43 payments
  3. Lilly USA, LLC $115 6 payments
  4. AbbVie, Inc. $111 4 payments
  5. Medtronic, Inc. $101 2 payments
  6. AstraZeneca Pharmaceuticals LP $75 3 payments
  7. Sanofi-Aventis U.S. LLC $54 2 payments
  8. Exact Sciences Corporation $29 1 payment
  9. Watermark Medical, Inc. $24 1 payment
  10. Amarin Pharma Inc. $23 1 payment
  11. Other $65 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $3,535 4 payments
  2. Food and Beverage $1,372 69 payments
Products named General payments · program years 2019–2025
  1. Ozempic $688 41 payments
  2. RYBELSUS $575 34 payments
  3. ClosureFast $85 1 payment
  4. MOUNJARO $80 4 payments
  5. VRAYLAR $61 2 payments
  6. TZIELD $54 2 payments
  7. UBRELVY $50 2 payments
  8. FARXIGA $49 2 payments
  9. Wegovy $49 2 payments
  10. ZEPBOUND $48 2 payments
  11. Other $316 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 171 drugs

Part D claims

10,926

Median for Internal Medicine: 777

Drug cost

$1,022,322

Median for Internal Medicine: $73,373

Branded share of claims

20.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 108 $154,455
Jardiance Empagliflozin Brand 115 $146,993
Xarelto Rivaroxaban Brand 84 $118,040
Eliquis Apixaban Brand 82 $110,304
Sandostatin Lar Depot Octreotide Acetate,mi-Spheres Brand 12 $54,795
Forteo Teriparatide Brand 11 $46,765
Trulicity Dulaglutide Brand 13 $19,558
Synjardy Empagliflozin/Metformin Hcl Brand 20 $18,578
Nuedexta Dextromethorphan Hbr/Quinidine Brand 12 $18,349
Atorvastatin Calcium Generic 954 $15,498

The 10 drugs with the highest cost, of 171 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$153,272

Of which drugs: $1,197

Medicare patients

592

Average age 76

Services billed

2,861

283 women, 309 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 27%
Ischemic heart disease 18%
Atrial fibrillation 16%
Cancer 16%
Chronic kidney disease 13%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 12 12 $982

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Ozempic
  • Novo Nordisk Inc $145
$145 108 —
RYBELSUS
  • Novo Nordisk Inc $128
$128 12 —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $54
$54 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $49
$49 — —
JARDIANCE
  • Lilly USA, LLC $35
$35 115 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

73 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record